Secondary Raynaud's phenomenon is associated with microvascular peripheral endothelial dysfunction.


Journal

Microvascular research
ISSN: 1095-9319
Titre abrégé: Microvasc Res
Pays: United States
ID NLM: 0165035

Informations de publication

Date de publication:
11 2020
Historique:
received: 17 06 2020
accepted: 09 07 2020
pubmed: 10 8 2020
medline: 16 12 2020
entrez: 10 8 2020
Statut: ppublish

Résumé

Previous studies in patients with Raynaud's phenomenon (RP) have found an association between microvascular abnormalities assessed by nail fold capillaroscopy and macrovascular peripheral endothelial dysfunction (PED), but the association between RP and nitric oxide related (NO) microvascular PED is not yet established. We performed a retrospective cross-sectional analysis of patients who were referred to Mayo Clinic between 2006 and 2014 for routine cardiovascular evaluation and who underwent evaluation of Reactive Hyperemia Peripheral Arterial Tonometry (index <2 consistent with PED). Identification of the presence of RP was determined by retrospective chart review. Six hundred sixty six individuals were included in this study (mean age 51.9 ± 13.5 years, 411 (61.3%) women), 637 (95.1%) individuals did not have RP (control group), and 29 (4.3%) had secondary RP. Only 4 patients had primary RP and were thus excluded from the final analyses. In a multivariate analysis adjusting for age, sex, smoking status, and use of statins we found a significant association between secondary RP and microvascular PED in all patients (Odds ratio: 2.45; 95% confidence interval 1.13-5.34; P = 0.0236) that remained significant in women after stratifying by sex. Secondary RP is associated with microvascular PED, detected using a non-invasive NO-dependent method. Early detection of microvascular PED could help in identifying individuals with secondary RP who are at risk for developing connective tissue disease as well as CVD.

Identifiants

pubmed: 32768463
pii: S0026-2862(20)30100-X
doi: 10.1016/j.mvr.2020.104040
pii:
doi:

Substances chimiques

Nitric Oxide 31C4KY9ESH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104040

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to disclose.

Auteurs

Riad Taher (R)

Division of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Jaskanwal D Sara (JD)

Division of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Takumi Toya (T)

Division of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Roger Shepherd (R)

Division of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Kevin Moder (K)

Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Lilach O Lerman (LO)

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

Amir Lerman (A)

Division of Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. Electronic address: lerman.amir@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH